Anti-Viral Therapies Market - Global Industry Analysis

Anti-Viral Therapies Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2026

Category: Pharmaceutical Report Format : PDF Report Code: ZMR-6273 Status : Upcoming

Description

Global Anti-Viral Therapies Market: Overview

Anti-viral therapy is an exciting part of virology, as it offers basic science to create very effective treatments for serious viral infections. Viral infections impose a socioeconomic burden, threaten public health, and leads to high mortality & morbidity. Anti-viral therapy is the best solution and also plays a crucial role in the management of neonatal and congenital viral infections.

Report Scope:

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Global Anti-Viral Therapies Market: Growth Factors

The global anti-viral therapies market is growing at a lucrative rate. Factors such as an increase in the burden of viral infections, the emergence of new strains & viruses resistant to available antivirals, and growing research & development activities are some of the factors that are propelling the growth of the global market. Further, the current outbreak of Covid-19 has led to a sudden boost in the demand for anti-viral therapies. The causative agent of Covid-19, SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2), by far has infected over 29 million people that has led to nearly 900 000 deaths. Additionally, the re-emergence of some viruses, the emergence of new viruses, the limited number of antivirals available, and the high prevalence of viral infections, research on new and effective antivirals have become very crucial. In addition to this, high genetic variations presented by some of the viruses have necessitated persistent monitoring for possible pandemics. In addition to this, globally, it is been projected that nearly 1.8 million people are infected with HIV. All these factors have led to a surge in the demand for anti-viral therapies thereby contributing to the growth of the global anti-viral therapies market. In addition to this, increase in preference for generic drugs, increase in the number of clinical trials for anti-viral therapies, rise in adoption of antiretroviral therapy, and increase in the funds to strengthen the pharmaceuticals clinical development pipeline are also some of the key aspects that are fueling the growth of the global market. Furthermore, the growing focus of the manufacturers on the development of investigational medicine for treating COVID-19 affected patients and the development of host-targeting antiviral therapies are likely to create numerous opportunities for the growth of the global anti-viral therapies market over the forecast period. However, the high cost associated with the anti-viral therapies may impede the growth of the global anti-viral therapies market.

The scenario of the entire world has been changed by the emergence of coronavirus disease of 2019 (COVID-19) pandemic. It has spread globally affecting millions of people at a rapid rate. Such a dreadful situation is demanding an efficient strategy to identify the drugs to treat the Covid-19 patients. Thus, there is a tremendous boost in the repurposing of antiviral drugs, and apart from this convalescent plasma therapy is used as a probable efficient antiviral strategy. In addition to this, increase in funds for antiviral therapies has been augmenting the growth of the global anti-viral therapies market during the pandemic and is anticipated to grow at a healthy rate in the upcoming years.

Global Anti-Viral Therapies Market: Segmentation

The global anti-viral therapies market is categorized based on mechanism of action, type, application, and region. Based on the mechanism of action, the global anti-viral therapies market is classified into protease inhibitors, reverse transcriptase inhibitors, nucleotide polymerase inhibitor, and others. The type segment is divided into branded drugs and generic drugs. The application segment consists of influenza, herpes virus, hepatitis, HIV, and others.

Global Anti-Viral Therapies Market: Regional Analysis

North America is expected to hold a prominent share in the global anti-viral therapies market and it’s anticipated the region will continue its dominance in the market over the forecast period. North America is among the highest purchaser of biological drugs and demand for antiviral drugs is always high in the region owing to large patient numbers suffering from HIV, influenza, hepatitis A, hepatitis B, and hepatitis C. In addition, high awareness regarding antiviral therapeutics is fuelling the market growth in North America. Asia Pacific is expected to be the most lucrative market for anti-viral therapies. The increasing prevalence of viral diseases in the region is among the major factor driving the growth of the market.

Global Anti-Viral Therapies Market: Competitive Players

Some of the predominant players that are operating in the global anti-viral therapies market include F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Johnson & Johnson, Aurobindo Pharma Limited, AbbVie Inc., AstraZeneca plc, Abbott Laboratories, Bristol-Myers-Squibb, GlaxoSmithKline, and Gilead Sciences.

Global Anti-Viral Therapies Market: Regional Segment Analysis

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

What Reports Provides

  • Full in-depth analysis of the parent market
  • Important changes in market dynamics
  • Segmentation details of the market
  • Former, on-going, and projected market analysis in terms of volume and value
  • Assessment of niche industry developments
  • Market share analysis
  • Key strategies of major players
  • Emerging segments and regional markets
  • Testimonials to companies in order to fortify their foothold in the market.

Table Of Content

Choose License Type

Request the coronavirus impact analysis across industries and markets

FrequentlyAsked Questions

Factors such as an increase in the burden of viral infections, the emergence of new strains & viruses resistant to available antivirals, and growing research & development activities are some of the factors that are propelling the growth of the global market. Furthermore, the growing focus of the manufacturers on the development of investigational medicine for treating COVID-19 affected patients and the development of host-targeting antiviral therapies are likely to create numerous opportunities for the growth of the global anti-viral therapies market over the forecast period.

Some of the predominant players that are operating in the global anti-viral therapies market include F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Johnson & Johnson, Aurobindo Pharma Limited, AbbVie Inc., AstraZeneca plc, Abbott Laboratories, Bristol-Myers-Squibb, GlaxoSmithKline, and Gilead Sciences.

North America is expected to hold a prominent share in the global anti-viral therapies market and it’s anticipated the region will continue its dominance in the market over the forecast period. North America is among the highest purchaser of biological drugs and demand for antiviral drugs is always high in the region owing to large patient numbers suffering from HIV, influenza, Hepatitis A, Hepatitis B, and Hepatitis C. In addition, high awareness regarding antiviral therapeutics is fuelling the market growth in North America.

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed